BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duquesne I, Weisbach L, Aziz A, Kluth LA, Xylinas E; Young Academic Urologist Urothelial Carcinoma Group of the European Association of Urology. The contemporary role and impact of urine-based biomarkers in bladder cancer. Transl Androl Urol 2017;6:1031-42. [PMID: 29354490 DOI: 10.21037/tau.2017.11.29] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Takke A, Shende P. Impregnation of dye-conjugated miniaturized system on paper strip for detection of biomarker in renal cancer. SR 2022. [DOI: 10.1108/sr-02-2022-0055] [Reference Citation Analysis]
2 Lokeshwar SD, Lopez M, Sarcan S, Aguilar K, Morera DS, Shaheen DM, Lokeshwar BL, Lokeshwar VB. Molecular Oncology of Bladder Cancer from Inception to Modern Perspective. Cancers (Basel) 2022;14:2578. [PMID: 35681556 DOI: 10.3390/cancers14112578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Zhu RJ, Zhou J, Liang PQ, Xiang XX, Ran J, Xie TA, Guo XG. Accuracy of cytokeratin 19 fragment in the diagnosis of bladder cancer. Biomark Med 2022. [PMID: 35112920 DOI: 10.2217/bmm-2021-0754] [Reference Citation Analysis]
4 Feldman AS, Lokeshwar V, Lin DW. A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers. Urol Oncol 2021:S1078-1439(21)00269-6. [PMID: 34315659 DOI: 10.1016/j.urolonc.2021.06.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Rodríguez-Serrano A, Carrión DM, Gómez Rivas J, Álvarez-Maestro M, Sánchez S, Rodríguez de Bethencourt F, Aguilera Bazán A, Martínez-Piñeiro L. Prognostic value of urinary cytology for detecting urothelial carcinoma recurrence after radical cystectomy. Actas Urol Esp (Engl Ed) 2021;45:466-72. [PMID: 34148845 DOI: 10.1016/j.acuroe.2021.06.001] [Reference Citation Analysis]
6 Loras A, Segovia C, Ruiz-Cerdá JL. Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer. Cancers (Basel) 2021;13:2719. [PMID: 34072826 DOI: 10.3390/cancers13112719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ding Z, Ying W, He Y, Chen X, Jiao Y, Wang J, Zhou X. lncRNA-UCA1 in the diagnosis of bladder cancer: A meta-analysis. Medicine (Baltimore) 2021;100:e24805. [PMID: 33725946 DOI: 10.1097/MD.0000000000024805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Georgantzoglou N, Pergaris A, Masaoutis C, Theocharis S. Extracellular Vesicles as Biomarkers Carriers in Bladder Cancer: Diagnosis, Surveillance, and Treatment. Int J Mol Sci 2021;22:2744. [PMID: 33803085 DOI: 10.3390/ijms22052744] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
9 Rodríguez-serrano A, Carrión D, Gómez Rivas J, Álvarez-maestro M, Sánchez S, Rodríguez de Bethencourt F, Aguilera Bazán A, Martínez-piñeiro L. Valor pronóstico de la citología urinaria en la recidiva del carcinoma urotelial vesical tras la cistectomía radical. Actas Urológicas Españolas 2021;45:466-72. [DOI: 10.1016/j.acuro.2020.11.002] [Reference Citation Analysis]
10 Kim SH, Lee HH, Seo HK. Urinary Biomarker in Bladder Cancer at Present Time. Korean J Urol Oncol 2020;18:183-193. [DOI: 10.22465/kjuo.2020.18.3.183] [Reference Citation Analysis]
11 Lee HH, Kim SH. Review of non-invasive urinary biomarkers in bladder cancer. Transl Cancer Res 2020;9:6554-64. [PMID: 35117265 DOI: 10.21037/tcr-20-1990] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
12 Oliveira MC, Caires HR, Oliveira MJ, Fraga A, Vasconcelos MH, Ribeiro R. Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles. Cancers (Basel) 2020;12:E1400. [PMID: 32485907 DOI: 10.3390/cancers12061400] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
13 Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney C, Grossman HB, Logothetis C, Scherer SE, Guo CC, Zhang L, Wei P, Weinstein JN, Issa JP, Baggerly K, McConkey DJ, Czerniak B. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep 2019;26:2241-2256.e4. [PMID: 30784602 DOI: 10.1016/j.celrep.2019.01.095] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
14 Yu X, Wang R, Han C, Wang Z, Jin X. A Panel of Urinary Long Non-coding RNAs Differentiate Bladder Cancer from Urocystitis. J Cancer 2020;11:781-7. [PMID: 31949480 DOI: 10.7150/jca.37006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
15 Takke A, Shende P. Non-invasive Biodiversified Sensors: A Modernized Screening Technology for Cancer. CPD 2019;25:4108-20. [DOI: 10.2174/1381612825666191022162232] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
16 Xu Y, Kim YH, Jeong P, Piao XM, Byun YJ, Kang HW, Kim WT, Lee JY, Kim IY, Moon SK, Choi YH, Yun SJ, Kim WJ. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urol Oncol 2019;37:86-96. [PMID: 30446454 DOI: 10.1016/j.urolonc.2018.10.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zaak D, Ohlmann C, Stenzl A. Die Diagnostik beim oberflächlichen Harnblasenkarzinom. Uro-News 2018;22:42-47. [DOI: 10.1007/s00092-018-1687-7] [Reference Citation Analysis]
18 Campi R, Seisen T, Roupret M. Unmet Clinical Needs and Future Perspectives in Non-muscle-invasive Bladder Cancer. Eur Urol Focus 2018;4:472-80. [PMID: 30172757 DOI: 10.1016/j.euf.2018.08.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
19 Krabbe L, Margulis V, Schrader AJ, Shariat SF, Gust KM, Boegemann M. Molecularly-driven precision medicine for advanced bladder cancer. World J Urol 2018;36:1749-57. [DOI: 10.1007/s00345-018-2354-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Zaak D, Ohlmann C, Stenzl A. Aktuelle und etablierte Diagnoseverfahren beim Harnblasenkarzinom. Urologe 2018;57:657-64. [DOI: 10.1007/s00120-018-0650-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 Szymańska K, Bosman FT, Hainaut P. Bladder Cancer. Pathology and Genetics, Diagnosis and Treatment. Reference Module in Biomedical Sciences 2018. [DOI: 10.1016/b978-0-12-801238-3.65315-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]